Laurus Labs to Hold its AGM on July 11

Laurus Labs Limited has announced that its 19th Annual General Meeting (AGM) will be conducted via video conference on July 11, 2024, at 3:00 PM IST. The AGM aims to address key agenda items including the adoption of audited financial statements for the fiscal year ending March 31, 2024, and the ratification of interim dividends already paid out.

Additionally, shareholders will vote on the appointment of directors and the remuneration of cost auditors for the financial year 2024-25. The meeting underscores Laurus Labs' commitment to transparency and governance in its operations.

Ordinary Business:

1. Adoption of audited Standalone Financial Statements for the year ended March 31, 2024.
2. Adoption of audited Consolidated Financial Statements for the year ended March 31, 2024.
3. Ratification of interim dividend on equity shares for the financial year 2023-24.
4. Ratification of 2nd interim dividend on equity shares for the financial year 2023-24.
5. Appointment of a Director in place of Mr. V V Ravi Kumar (DIN 01424180) who retires by rotation.

Special Business: 

• Approval of remuneration payable to Cost Auditors for the financial year ending 2024-25. 
• Appointment of Mr. Krishna Chaitanya Chava as Director. 
• Appointment of Ms. Soumya Chava as Director.  
• Approval of the appointment of Mr. Krishna Chaitanya Chava (DIN 06831883) as Executive Director of the Company. 
• Approval of the appointment of Ms. Soumya Chava (DIN 06831892) as Executive Director of the Company. 
• Approval of the appointment of Mr. Karnam Sekar as Independent Director for a period of 5 years.

These agendas will be deliberated upon during the AGM scheduled for July 11, 2024, via video conference.

Read the full notice by clicking here.

Laurus Labs Annual Report 2023-24

Laurus Labs, a prominent pharmaceutical company, has released its Annual Report for the fiscal year 2023-24. Laurus Labs initially focused on contract research and manufacturing services (CRAMS) and quickly gained recognition in the antiretroviral (ARV) domain.

Over the years, the company expanded its expertise to become a global leader in active pharmaceutical ingredients (APIs) and integrated pharmaceutical solutions, including biotechnology.

The Annual Report highlights Laurus Labs' commitment to leveraging its core capabilities in chemistry, formulation, and custom synthesis to enhance quality and affordability in the pharmaceutical industry. The company now serves a diverse range of sectors, including pharmaceuticals, animal health, cosmetics, dietary supplements, and crop science.

For more detailed information on Laurus Labs' performance and strategic initiatives in the fiscal year 2023-24, you can access the full Annual Report by clicking the link here.

Laurus Labs 

Laurus Labs, founded in 2005, has rapidly emerged as a prominent player in the pharmaceutical industry, focusing on the development and manufacturing of Active Pharmaceutical Ingredients (APIs) and intermediates. The company's journey to prominence includes achieving leadership in critical therapeutic segments such as anti-retroviral (ARV), oncology, cardiovascular, and gastro therapeutics. 

Beyond pharmaceuticals, the company has diversified into biotechnology and biologicals through its subsidiary, Laurus Bio, investing in advanced therapies like Cell and Gene therapies. With a steadfast focus on environmental stewardship and corporate governance, Laurus Labs continues to advance healthcare solutions while fostering a culture of integrity and responsibility across its global operations.